Back to trial detailsIntake questionnaire
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
Applying to Memorial Sloan Kettering Cancer Center · New York, New York
Answer a few short questions to share with the research team.
0 of 4 answered